

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/030615 A1

(51) International Patent Classification:

A61K 31/4725 (2006.01) A61K 45/06 (2006.01)
A61P 9/12 (2006.01)

(21) International Application Number:

PCT/US2023/029493

(22) International Filing Date:

04 August 2023 (04.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/395,680	05 August 2022 (05.08.2022)	US
63/374,410	02 September 2022 (02.09.2022)	US
63/378,120	03 October 2022 (03.10.2022)	US
63/384,594	21 November 2022 (21.11.2022)	US
63/386,683	09 December 2022 (09.12.2022)	US

(71) Applicant: CINCOR PHARMA, INC. [US/US]; 1800
Concord Pike, Wilmington, Delaware 19850 (US).

(72) Inventor: PEARCE, Catherine; 7781 Campus Lane,
Cincinnati, Ohio 45242 (US).

(74) Agent: EATON, James et al.; Astrazeneca Medimmune,
One MedImmune Way, Gaithersburg, MD 20878 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF TREATING HYPERTENSION WITH THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT

(57) Abstract: The disclosure provides methods of treating hypertension in a subject in need thereof, comprising administering baxdrostat.

WO 2024/030615 A1